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ABSTRACT
We investigated the relationship between the result of technetium-99m-methoxyisobutylisonitrile
(MIBI) parathyroid scanning and the subsequent biochemical outcome following calcitriol treatment.
Twenty-two patients on dialysis with serum intact parathyroid hormone (PTH) level (iPTH) more
than 500 pg/mL on annual checkup were selected. Around 20 weeks later, baseline iPTH were
repeated at the time of performing MIBI scan and assayed again another 20 weeks later, while
patients had intensification of treatment with oral calcitriol. Ten had positive MIBI parathyroid
scans (MIBI+) while 12 had negative MIBI parathyroid scans (MIBI-). Although there was no
statistically significant difference between both groups concerning baseline iPTH, phosphate, calcium
x phosphate product and aluminum level, the MIBI+ group had higher serum calcium level and a
tendency toward longer duration of dialysis. At 20 weeks, the MIBI- group showed a significantly
lower iPTH of 413.2 ±335.7 pg/mL as compared to the MIBI+ group of 884.6 ±706.6 pg/mL
(p = 0.03). The MIBI-group also had a higher proportion of patients showing decrease in iPTH (p =
0.05). Despite more profound iPTH suppression, the MIBI- group was actually given a lower mean
maximum weekly calcitriol dosage of 2.20 ±1.82 µg as compared to 4.33 ±2.15 µg in the MIBI+
group (p = 0.025). Excessive suppression of iPTH below 100 pg/mL was evident in two patients of
the MIBI- group and none in the MIBI+ group. We concluded that for patients on dialysis with
grossly elevated baseline iPTH, the biochemical response to calcitriol is more profound in the MIBI-
group. MIBI parathyroid scan may provide supplementary hints concerning the outcome of the
medical treatment for uremic hyperparathyroidism.
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INTRODUCTION
Technetium-99m-methoxyisobutylisonitrile (MIBI)
scintigraphy has recently been used as an alternative
method to 201Tl/99mTc pertechnetate subtraction
scintigraphy for parathyroid imaging (1). Figure 1
represents a MIBI parathyroid scan showing persistent
uptake at the left lower parathyroid gland, whereas figure
2 represents a similar scan showing multiple persistent
uptake at the left upper and lower parathyroids as well
as the right lower parathyroid gland. Figure 1 and 2 are
thus compatible with a solitary parathyroid adenoma and
parathyroid hyperplasia, respectively.
MIBI is concentrated within the cells through active
transport and passive diffusion just like thallium (2).
Nevertheless, the lipophilic nature of MIBI facilitates
transmembrane passage in a manner superior to thallium.
It has been shown that intramitochondrial sequestration
of MIBI is pivotal in affecting its binding to parathyroid
tissue (3). Previous studies have demonstrated the
presence of many mitochondria in hyperactive
parathyroid oxyphil cell (4). This probably explains why
there is slower MIBI washout from hyperactive
parathyroid tissues as compared to the normal
parathyroid and thyroid tissue (5).  Since the
establishment of double-phase procedure of MIBI
parathyroid imaging by Taillefer et al (6), other workers
have also suggested that MIBI parathyroid imaging
reflect not the size but the degree of functional autonomy
of the parathyroids in the context of secondary
hyperparathyroidism (7).  In fact,  i t  has been
demonstrated that the late retention of 99m-technetium-
MIBI in double-phase scintigraphy is related to
parathyroid oxyphil cell content (8). Despite the
apparently superior imaging potential for detecting
primary parathyroid adenoma, the MIBI parathyroid scan
has a surprisingly low sensitivity for detection of
hyperplastic or adenomatous parathyroid in uremia.
According to the study by Mario et al in nine uremic
patients with positive MIBI parathyroid scan (MIBI+)
in whom there were grossly elevated intact parathyriod
hormone (iPTH), parathyroidectomy yielded a total of
27 hyperplastic parathyroid glands and one parathyroid
adenoma (7). The MIBI scan correctly identified the
adenoma but was only effective in identifying 12 of the
27 (44%) hyperplastic parathyroid glands. Another study
by Torregrosa et al also suggested that the sensitivity
and specificity of MIBI parathyroid scan in the context
of secondary hyperparathyroidism were about 41% and
89%, respectively (9). Hence, it is apparent that MIBI
parathyroid scan would not be an ideal tool for
anatomical localization of hyperplastic or adenomatous
glands in uremia. However, we speculate that the MIBI
parathyroid scan may have a role as a prognostic indicator
for the likelihood of obtaining favorable response to
medical treatment. To test this hypothesis, we
prospectively followed the clinical courses of patients
on dialysis with severe biochemical hyperparathyroidism
and compared the biochemical outcome following
intensification of calcitriol treatment between the positive
(MIBI+) and negative MIBI parathyroid scan (MIBI-)
groups.
PATIENTS AND METHODS
In November 1997, we had about 170 patients on either
hemodialysis (HD) or continuous ambulatory peritoneal
dialysis (CAPD) in the renal unit of Tuen Mun Hospital,
Hong Kong. We usually prescribe phosphate binders to
patients on dialysis whenever the serum phosphate is
more than 1.5 mmol/L. Aluminum hydroxide would first
be prescribed, eventually substituted by calcium
carbonate if possible. Calcitriol is usually added if serum
alkaline phosphatase is more than 150 iu /L (with normal
gamma GT) or if iPTH is more than 200 pg/mL (reference
range of iPTH for our laboratory is 11 pg/mL - 54 pg/
mL). We had routine yearly screening of iPTH for all
patients on dialysis. During the annual screening in
November 1997, 30 patients were found to have iPTH
more than 500 pg/mL (i.e. 10 times more than the upper
limit of its reference range). We originally intended to
enroll all these 30 patients into our study to have the
MIBI parathyroid scans performed. However, of these
30 patients, one refused parathyroid scan because of
claustrophobia, four were transplanted during the study
period while three were excluded because of faulty blood
taking. Finally, 22 patients were available for analysis.
Intact PTH (iPTH) levels were measured with a two-site
chemiluminescent immunoassay on the Magic-Lite
System (Chiron Diagnostics Corporation, East Walpole,
MA 02032, USA). It had an "intra-assay coefficient of
variation" of 5.8% at 18.9 pg/mL and 4.4% at 306.6 pg/
mL. The "inter-assay coefficient of variations" was
14.8% at 18.5 pg/mL and 5.5% at 347.1 pg/mL. The assay
"analytical sensitivity" was 1.4 pg/mL.
As there was no iPTH assay available in Tuen Mun
Hospital, all the iPTH assays were performed in Queen
Mary Hospital. The results of iPTH assays were only
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available after around 10 weeks. By the time we selected
out those patients with iPTH more than 500 pg/mL and
arranged MIBI parathyroid scans for them, it was already
20 weeks following the annual iPTH screening. Calcium,
phosphate, iPTH and aluminum levels were checked on
the same day when MIBI parathyroid scans were
performed, serving as the baseline levels. A patient was
categorized to be MIBI+ if the MIBI parathyroid scan
yielded patterns suggestive of either solitary parathyroid
adenoma or diffuse parathyroid hyperplasia (Fig. 1,2).
On the other hand, one was classified to be MIBI- if the
MIBI parathyroid scan result was negative. The serum
iPTH, calcium and phosphate were repeated 20 weeks
(arbitrarily taken) after intensification of medical
treatment with calcium carbonate and calcitriol. All the
serum calcium levels were corrected with reference to
the serum albumin level [corrected serum calcium level
= measured serum calcium level + (40 g/L - serum
albumin level in g/L) x 0.02]. During the period, patients
were followed up once every 2 to 4 weeks. Aluminum
hydroxide were stopped or decreased wherever possible.
Calcium carbonate was added to control serum phosphate
level less than 2 mmol/L. Since all of the enrolled patients
had grossly elevated iPTH in November 1997, oral
calcitriol was either added or to increase from regular
daily dose to two to three pulses per week. The dosage
was increased gradually from 0.25 µg/day up to 2.5 µg
three times per week trying to achieve a normal serum
alkaline phosphatase level as long as patients’ serum
calcium  was not  more than 2.8 mmol/L. Calcitriol would
be readily given in pulse form whenever the baseline
corrected serum calcium was on the high side while the
serum alkaline phosphatase remained elevated. The
calcitriol treatments were reviewed when the baseline
iPTH results were available after around 15 weeks.
Although the baseline iPTH was persistently more than
500 pg/mL in most cases, there was decreases in iPTH
down to below 500 pg/mL in three cases of each category.
This was either due to laboratory variation or routine
medical treatments. Calcitriol would be stopped if the
baseline iPTH turned out to be below 100 pg/mL.
Otherwise, the calcitriol doses would be either
maintained or intensified accordingly.
The baseline biochemical parameters and the
corresponding parameters after intensification of
treatment between MIBI+ and MIBI- groups were then
compared. The post-treatment iPTH, the relative
proportion of increase or decrease of iPTH and
percentage change of iPTH were compared between these
two groups. We defined the percentage change in iPTH
as [(iPTH at 20 weeks minus iPTH at baseline)/ iPTH at
baseline] x 100%. As most of our patients were receiving
escalating doses of calcitriol, we arbitrarily employed
the maximum weekly dosage of calcitriol as a parameter
to indicate the intensity of medical treatment given during
the study period. Again, this parameter was compared
between the MIBI+ and MIBI- groups.
All our results were expressed as mean ±SD unless
otherwise stated. All data were compared by standard
descriptive statistics including Mann-Whitney test or
Fisher's exact test where appropriate. Probabilities were
two-tailed and p values below 0.05 were regarded as
statistically significant.
RESULTS
Of the 22 patients studied, 10 had positive while 12 had
negative MIBI parathyroid scan. Of the 10 patients with
positive scan, one was compatible with adenoma (Fig.
1) whereas the other nine were compatible with
hyperplasia showing multiplicity of foci with delayed
washout (Fig. 2).
The demographic characteristics of the two groups were
tabulated in table 1. There was no difference in the sex
ratio, prevalence of diabetes mellitus and the mode of
Figure 1.  MIBI parathyroid scan showing persistent uptake at the
lower pole of left lobe of thyroid.
Figure 2.  MIBI parathyroid scan showing multiple persistent
uptakes at the left upper pole and both lower poles of the thyroid
gland.
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dialysis between the two groups. Concerning the duration
of dialysis  and the radiological  evidence of
hyperparathyroidism, although the difference between
the two groups did not reach statistical significance, there
seemed to be a tendency of longer duration of dialysis
with radiological evidence of hyperparathyroidism in the
MIBI+ group. All the skeletal surveys were reported
independently by radiologists. Positive radiological
evidence of hyperparathyroidism includes subperiosteal
resorption of the phalanges, upper end of the tibia, the
neck of the femur or humerus, the lower end of the radius
or ulna, and the lower surface of the medial end of the
clavicle. There was no observable difference between
the two groups in baseline aluminum, phosphate, calcium
x phosphate product, phosphate after 20 weeks and
calcium x  phosphate product after 20 weeks.
Nevertheless, the MIBI- group had significantly lower
serum calcium level than the MIBI+ group at baseline
(2.325 ±0.223 mmol/L vs 2.622 ±0.204 mmol/L) and
after 20 weeks of intensified medical intervention
(2.498 ±0.180 mmol/L vs 2.769 ±0.386 mmol/L) with p
values of 0.006 and 0.04, respectively. The comparison
of parameters related to parathyroid hormones and
calcitriol treatment between the two groups was tabulated
in table 2. Although there was no difference in the
baseline iPTH between the MIBI- and MIBI+ groups
(892.7 ±638.6 pg/mL vs 1213.8 ±978.8 pg/mL with p =
0.58), the former iPTH level after 20 weeks was
significantly lower than that of the latter (respectively
413.2 ±335.7 pg/mL vs 884.6 ±706.6 pg/mL with p =
0.03). Concerning the percentage change in iPTH, the
MIBI+ group had 66.6 ±284.5% increase in iPTH after
intensification of medical treatment while the MIBI-
group had 56.1 ±29.8% decrease. The data in the MIBI+
group was skewed by patient 6 who actually was found
to have a very high baseline aluminum level at up to 5.6
µmol/L (normal < 0.6 µmol/L). While on pulse oral
calcitriol up to a dosage of 4.5 µg/week, her baseline
iPTH at the time of performing MIBI parathyroid scan
turned out to be only 67 pg/mL. With the knowledge of
the inappropriately low iPTH and the abnormally high
serum aluminum level, chelating treatment in terms of
six weekly doses of 350 mg intraperitoneal deferoxamine
was started. The iPTH subsequently rebounded to 650
pg/mL after 20 weeks with serum aluminum level falling
below 2 µmol/L. There were no significant elevations
of serum aluminum level for the rest of the patients, nor
was bone biopsy done in any one of them. If we excluded
patient 6 from our analysis, the MIBI+ group had a
22.7 ±37.2% drop in iPTH. That was still significantly
higher than the MIBI- group with p value of 0.04.
Furthermore, in the MIBI+ group, five out of 10 patients
Table 1.  Comparison of patient demographics and serum biochemistry profiles between the MIBI+ and MIBI- groups.
MIBI+ group (N = 10) MIBI- group (N = 12) p value
Sex ratio (M:F) 3:7 4:8 1.0*
Duration of dialysis (months) 38.9 ±12.0 29.0 ±15.1 0.12#
Mode of dialysis (CAPD:HD) 8:2 11:1 0.57*
Diabetes mellitus as cause of ESRF 2 1 0.57*
Radiological evidence of hyperparathyroiodism 7 4 0.20*
Baseline aluminum (µmol/L) 1.543 ±1.704 0.473 ±0.333 0.12#
Baseline corrected calcium (mmol/L) 2.622 ±0.204 2.325 ±0.223 0.006#
Baseline PO4 (mmol/L) 1.939 ±0.369 2.0 ±0.729 0.77#
Baseline Ca x PO4 5.098 ±1.128 4.660 ±1.840 0.63#
Corrected calcium after 20 weeks (mmol/L) 2.769 ±0.386 2.498 ±0.180 0.04#
PO4 after 20 weeks (mmol/L) 2.097 ±0.664 1.927 ±0.722 0.63#
Ca x PO4 after 20 weeks 5.685 ±1.462 4.751 ±1.656 0.18#
NB: #based on Mann-Whitney's tests; *based on Fisher's Exact tests
Table 2.  Comparison of iPTH profiles and calcitriol treatment between the MIBI+ and MIBI- group.
MIBI+ group (N = 10) MIBI- group (N = 12) p value
Baseline iPTH (pg/mL) 1213.8 ±978.8 892.7 ±638.6 0.58#
iPTH after 20 weeks (pg/mL) 884.6 ±706.6 413.2 ±335.7 0.03#
% Change in iPTH  +66.6 ±284.5 -56.1 ±29.8 0.02#
% Change in iPTH (omitting patient no.6) -22.7 ±37.2 -56.1 ±29.8 0.04#
Increased/decreased iPTH despite Px 5/5 1/11 0.05*
Proportion on pulse calcitriol 8/10 5/12 0.10*
Maximum weekly oral calcitriol dose given 4.325 ±2.154 2.204 ±1.817 0.025#
NB: #based on Mann-Whitney's tests; *based on Fisher's exact tests
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showed a drop in iPTH with treatment whereas 11 out of
12 patients in the MIBI- group showed a drop in iPTH
with p value at 0.05. Eight out of 10 patients in the MIBI+
group were given calcitriol in form of pulse therapy while
only five out of 12 in the other group did so with p value
at 0.10. However, the maximum weekly oral calcitriol
dose given in the MIBI+ and MIBI- groups were 4.325
±2.154 µg and 2.204 ±1.817 µg, respectively, with p
value at 0.025. The exact values of iPTH at the time of
annual checkup, at the time of performing MIBI scan
and at 20 weeks after intensification of medical treatment
were tabulated in table 3. Interestingly, there were three
cases in either groups demonstrating a spontaneous fall
in iPTH below 500 pg/mL at the time when the MIBI
scans were performed.
DISCUSSION
Owing to the small sample size in this preliminary study,
it is not expected to draw a definite conclusion about the
effectiveness of MIBI parathyroid scan as a tool to predict
clinical outcome. Nevertheless, we wish to illustrate how
the MIBI parathyroid scan may help to shed some light
on the probable treatment outcome in patients with
hyperparathyroidism, especially when frequent serial
iPTH assays are not readily available.
Our data had shown that the MIBI+ group tended to have
a longer duration of dialysis and a positive radiological
evidence of hyperparathyroidism in skeletal survey
though the difference did not reach statistical significance
(see table 1). Furthermore, despite a relatively
comparable iPTH at baseline, the MIBI- group had a
more significant percentage drop in iPTH in response to
intensification of medical treatment. The actual post-
treatment iPTH and the proportion of patient whose
subsequent iPTH did not drop below the baseline were
significantly lower in the MIBI- group as compared to
the MIBI+ group. Despite a higher iPTH after
intensification of medical treatment in the MIBI+ group,
the group actually had a significantly higher serum
calcium level while requiring a significantly higher
dosage of calcitriol. There was also a tendency for the
MIBI+ group to require more pulses rather than daily
calcitriol therapy (see table 2). This shows that
hyperparathyroidism in uremia represented a
hyperfunctioning state with nonsuppressible iPTH that
did not respond to physiological regulation (such as
hypercalcemia) and pharmacological regulation by
calcitriol (7) - a finding that aligns with those from
previous authors. It has also been shown that the enzyme
adenylyl cyclase in parathyroid cell membranes prepared
from hyperplastic parathyroid glands is less susceptible
Table 3.  Comparison of the baseline iPTH between the MIBI+ and MIBI- groups.
Patient number Annual Baseline After 20 weeks
MIBI+ group
iPTH in pg/mL at various time points 1 1870 2700 1600
2 2080 940 780
4 1440 2400 695
  6* 570 67 650
13 670 725 147
16 600 319 374
18  655 1490 890
19 680 2440 2570
20 725 362 435
22 715 695 705
MIBI- group
iPTH in pg/mL at various time points 3 1840 1230 585
5 510 565 144
7 500 90 16
8 890 2370 1150
9 710 760 424
10 875  830 360
11 905 905 269
12 515 310  25
14 800 875 765
15 610 550 615
17 765 1770 496
21 840 457 113
*Patient number 6 was given DFO for treatment of aluminum overload during study period.
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to inhibition by calcium than that of membranes prepared
from normal parathyroid tissue (10). The altered response
of parathyroid cells to calcium was also attributed to the
decrease in calcium-sensing receptor up to 59% in
parathyroid glands of uremic patients (11,12). On the
other hand, a recent paper suggested that chronic
hypermagnesemia may decrease iPTH secretion and/or
synthesis (13). Unfortunately, no data was available
concerning the magnesium level in our patients.
In view of the small number of patients enrolled in this
study with its inherent limitation of low statistical power,
any impression or suggestions from this study should
not be taken as conclusive. Moreover, this study only
focues on the short-term (20 weeks) biochemical
responses after intensified medical therapy. Therefore,
whether the MIBI parathyroid scan can predict
histological regression of parathyroid hyperplasia and
improvement of osteitis fibrosa remains to be elucidated
by a larger scale and longer term studies. Preferably these
studies should also touch on surgical outcomes such as
the incidence of parathyroidectomy as well as the
correlation between surgical parathyroid pathology and
MIBI parathyroid scan.
Owing to logistic reasons, we could not obtain the result
of iPTH within a reasonably short period of time. Hence,
when MIBI parathyroid scan was performed in response
to a routine yearly iPTH screening, there was already
spontaneous drop in some patients. It is thus advisable
to obtain the iPTH result within a reasonably short period,
say 1 week, then ask for the MIBI parathyroid scan to
obtain some supplementary information as to the severity
of the parathyroid lesions.
Another interesting observation was that two non-
diabetic patients (patient no. 7 and 12) in the MIBI- group
already had a significant drop of iPTH at the time of
performing MIBI parathyroid scan to 90 pg/mL and 310
pg/mL, respectively. Their iPTH subsequently fell further
to 16 pg/mL and 25 pg/mL even after the low dosage of
daily calcitriol was stopped. Although this was within
the reference range for non-uremic patients (i.e. 11 pg/
mL - 54 pg/mL), the iPTH was in fact subnormal in
uremia. It has been suggested that the reference range
for iPTH in uremia should be about 100 pg/mL to 150
pg/mL (14). These patients are in fact at risk of
developing adynamic bone disease because of excessive
suppression of the parathyroid hormone. Their calcitriol
treatment should hence be stopped promptly. In fact, it
was suggested that too early and aggressive treatment of
initial hyperparathyroidism should be avoided and
tolerance to a mild elevation of iPTH should be allowed
(15). On the other hand, none of the 10 MIBI+ patients
subsequently became over-treated even with pulse
calcitriol therapy. Of course, to avoid over-treatment of
hyperparathyroidism with calcitriol as in the two
previously mentioned patients, it would be mandatory
to have a standard guideline of treatment and more
frequent iPTH assays with prompt availability of results.
Our data suggested that the MIBI- group was especially
vulnerable to over-treatment as comparable to the MIBI+
group. Hence MIBI scan may help to shed some lights
on the potential clinical outcome which in turn may affect
the aggressiveness of our medical treatment. Our findings
actually confirmed with the findings of Ambrosoni et al
that the MIBI parathyroid scan would be of value in
functional studies when a therapeutic decision must be
made (16). Hence, apart from pure anatomical
localization, MIBI parathyroid scan may enable us to
assess the functional status of the parathyroids and
subsequent clinical response to medical therapy, so that
appropriate proactive adjustment is possible.
In summary, the MIBI parathyroid scan was able to
identify a subgroup of patient with gross elevation of
iPTH at baseline, whose iPTH secretion were more
autonomic and resistant to suppression despite a higher
serum calcium level and the use of a higher dosage of
calcitriol. We concluded that in dialysis patients with
grossly elevated iPTH (> 500 pg/mL) detected on routine
screening, the short-term biochemical response to
calcitriol treatment is more effective in the MIBI- group.
MIBI parathyroid scan can thus provide supplementary
information to assess the likelihood of successful medical
treatment for uremic hyperparathyroidism.
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